In colorectal cancer (CRC), METTL3-mediated m6A modification enhances the binding of Sec62 with β-catenin, thereby enhancing Wnt signal transduction, promoting CRC stemness, and augmenting chemotherapy resistance [58]. Here, SEC62 is linked to colorectal carcinoma.